Efficacy and safety of orally soluble pellicles of ondansetron in preventing nausea and vomiting after total joint arthroplasty
- Conditions
- knee osteoarthritis
- Registration Number
- ChiCTR2400088859
- Lead Sponsor
- West China Hospital,SCU
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Patients aged 40 to 80 years who received their first unilateral TJA for primary hip or knee osteoarthritis were enrolled in the trial.
The exclusion criteria were any one of the following: (1) history of allergy to study drugs, (2) use of systemic steroids or antiemetics within 24 hours preoperative, (3) a history of steroid or immunosuppressive drug use within the first 6 months, (4) a history of gastrointestinal disease, such as reflux esophagitis, gastroduodenal ulcer, or severe impairment of gastrointestinal motility, (5) poor control of blood glucose and blood pressure; (6) Combining other diseases such as Meniere syndrome that may cause nausea and vomiting; (7) participating in other trials or is expected to have insufficient compliance.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method postoperative nausea and vomiting;
- Secondary Outcome Measures
Name Time Method inflammatory biomarkers;the dosage of metoclopramide;the dosage of tramadol;common adverse drug reactions (ADRs) associated with serotonin receptor antagonists, namely pruritus, dizziness, headache, cardiac arrhythmias, and extrapyramidal signs;